Evaluation of clinical, ultrasonographic, and clinicopathological findings in dogs with pituitary-dependent hypercortisolism and poor trilostane response
Journal of Veterinary Internal Medicine · 2026
DOI: 10.1093/jvimsj/aalag096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, 2026. Verfasst von Stefania Golinelli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, Bologna, Italy. Hauptthemen laut MEDLINE: Dog Diseases, Dihydrotestosterone, Pituitary ACTH Hypersecretion. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Trilostane is the treatment of choice for pituitary-dependent hypercortisolism (PDH) in dogs, but predictors of a poor response are unclear. Hypothesis/Objectives To identify variables associated with a poor response to trilostane in dogs with PDH. Animals Twenty-three dogs with PDH treated with trilostane.
Methods
Retrospective cohort study. Clinical, clinicopathological, endocrine, ultrasonographic, and treatment data were reviewed. Dogs were classified as good responders (GRs) or nonresponders (NRs) based on clinical outcomes after 4-8 months of trilostane treatment. The primary outcome was treatment response.
Results
Fifteen dogs were GRs and 8 were NRs. At diagnosis, GRs had lower alanine aminotransferase (ALT) (median [IQR] 182 [70-251] vs 330 [224-578] U/L; P = .004), eACTH (14.4 [9.25-29.13] vs 49.2 [34.35-62.35] pg/mL; P = .007), and pre-ACTH cortisol (4.28 [3.07-6.52] vs 9.0 [6.57-19.40] μg/dL; P = .019) than NRs. Bilateral adrenomegaly was more frequent in NRs (8/8) than in GRs (9/15; P = .007). At T1, NRs required more rechecks (median [IQR] 7 [6-7] vs 3 [3-5]; P < .001) and higher trilostane doses (3.25 [3-5.75] vs 1.22 [0.66-1.60] mg/kg q12h; P < .001). After false discovery rate adjustment, ALT, eACTH, alopecia, and bilateral adrenomegaly remained significant (q = 0.047 for each). All GRs achieved complete clinical resolution within 4 months of treatment initiation. Conclusions and clinical importance Higher baseline ALT, eACTH, and pre-ACTH cortisol, as well as bilateral adrenomegaly, were associated with a poor response to trilostane. A lack of improvement by 4-8 months and the need for higher doses or more rechecks supports early therapeutic reassessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, Bologna, Italy.
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Lisbon, Portugal.
- Antech Imaging Services, Irvine, CA, United States.
- Department of Medicine and Epidemiology School of Veterinary Medicine, University of California, Davis, CA, United States.
Zitieren
APA
Golinelli, S., Fracassi, F., Del Baldo, F., Leal, R. O., Pey, P., & Feldman, E. C. (2026). Evaluation of clinical, ultrasonographic, and clinicopathological findings in dogs with pituitary-dependent hypercortisolism and poor trilostane response. Journal of Veterinary Internal Medicine. https://doi.org/10.1093/jvimsj/aalag096
Vancouver
Golinelli S, Fracassi F, Del Baldo F, Leal RO, Pey P, Feldman EC. Evaluation of clinical, ultrasonographic, and clinicopathological findings in dogs with pituitary-dependent hypercortisolism and poor trilostane response. Journal of Veterinary Internal Medicine. 2026. doi:10.1093/jvimsj/aalag096
BibTeX
@article{Golinelli2026,
author = {Golinelli, Stefania and Fracassi, Federico and Del Baldo, Francesca and Leal, Rodolfo Oliveira and Pey, Pascaline and Feldman, Edward C},
title = {Evaluation of clinical, ultrasonographic, and clinicopathological findings in dogs with pituitary-dependent hypercortisolism and poor trilostane response},
journal = {Journal of Veterinary Internal Medicine},
year = {2026},
doi = {10.1093/jvimsj/aalag096}
}
EUVIMED